About Us

Sundaresh has over 26 years of experience in leadership roles across various organizations in Finance, Business Management, Regulatory Compliance, Manufacturing, Sourcing and Administration. He has been associated with the life sciences industry for more than two decades. Sundaresh conceptualized and established state-of-the-art vivarium and BSL2 labs in TheraIndx. He has been instrumental in establishing systems & processes and obtaining regulatory compliance & accreditations at TheraIndx. He provides overall leadership, develops and sustains partnerships with key customers, suppliers and global stake holders.

Dhanalakshmi (Lakshmi) is the CSO of TheraIndx Lifesciences, a leading CRO in Bangalore, India. Lakshmi has close to 25 years of experience in the field of Oncology. She is an inventor on over 10 patents and has published about 30 research articles in reputed peer-reviewed journals.
Prior to TheraIndx, she led the Discovery Biology at Jubilant Therapeutics and played a key role in discovery and clinical transition of their proprietary molecules in the area of Oncology and autoimmune disorders. Prior to that she was heading the Oncology therapeutic area at Jubilant Biosys Ltd., where she executed about 25 Oncology discovery projects delivering multiple milestones, including three pre- clinical candidates. She was also instrumental in out-licensing two of the in-house projects to US-based Biotech companies. Before joining Jubilant in 2007, Lakshmi has completed post-doctoral trainings at the National Cancer Center, Tokyo, Japan and at the University of Colorado Health Sciences Center, Denver, USA. She received her Ph.D. in Life Sciences (Cancer research) from Jawaharlal Nehru University, New Delhi, India and Masters degree in Biomedical Genetics from Madras University, Chennai, India.

Ramesh has over 23 years of experience in Drug Discovery and Development in critical therapeutic areas like oncology & infection. His core expertise lies in Biochemistry, Pharmacokinetics and Pharmacodynamics. He has played a pivotal role in global drug discovery programs at organisations like AstraZeneca & S*Bio. As a Senior Scientist and Team Leader in S*BIO Pte Ltd Singapore, Ramesh was responsible for preclinical development, PK, ADME, and toxicology for three small molecule targeted anticancer clinical development candidates - Pacritinib in Phase III trials for Myelofibrosis, Pracinostat in Phase II trials for solid tumors and TG02 in Phase II trials for lymphoma. Ramesh has been at the core in anti-tuberculosis drug discovery during his stint as Research Scientist and Team Leader at AstraZeneca India Pvt Ltd. He is an expert in PK, PD and PK/PD, managing lead identification and optimization projects, modeling and simulation. He has 18 publications including a book chapter in reputed International Journals. Ramesh heads scientific operations at TheraIndx.

Mahesh has over 21 years of global experience in Drug Discovery & Development. He has been associated with Novartis & AstraZeneca. His expertise lies in the areas of PK/PD, animal models for Malaria, Dengue, African Trypanosoma, Tuberculosis, broad spectrum anti-infectives, Diabetes and medical device development. He has managed BSL-2 & BSL-3 laboratories and is well versed with animal welfare, HSE, biosafety policies pertaining to US, Europe, Singapore & India. He is an expert in regulatory compliance for GLP & AAALAC. Mahesh heads discovery biology at TheraIndx.

Dr. S. R. Ashok has over 16 years of combined experience in API process development, custom synthesis, Natural products extractions, Drug Discovery & Development. He has worked with Apotex India Pvt. Ltd., Alkem Laboratories & Cipla in his sixteen years’ journey. He has expertise in Critical API process development and execution of plant validation batches, wide verities of chemical synthesis from milligram to kilograms. Rich experience in synthesis of API process impurities, metabolites and genotoxic impurities.

Mahesh is a Masters in Pharmacology with over 8 years of experience in Drug Discovery & Development. His areas of expertise include ADMET-PK,Toxicology, Safety Pharmacology, animal models for Infection, Kidney Disorders & Bio-Assays. He is proficient in animal welfare, biosafety policies and regulatory compliance for AAALAC and GLP. He is an expert in surgical and other interventional procedures in animal models. Mahesh Kumar leads pharmacology at TheraIndx.

Ramesh is a highly accomplished microbiologist with a Master’s degree and over twelve years’ of industry experience. He possesses expertise in Cell biology, Molecular biology, In vitro and in vivo pharmacology. Ramesh is also well-versed in biosafety policies and regulatory compliances for Good laboratory practices.

Saroj Singh is a distinguished leader in the Contract Research Services Industry, renowned for his expertise in business development, strategic planning and deal making. Saroj holds Master’s Degree in Molecular Biology and Genetic engineering and Management Degree in Sales and Marketing. With over 17 years of invaluable experience, Saroj has made significant contributions to the growth and success of prominent CRO organizations. His key expertise includes proficiency in identifying growth opportunities, forging strategic alliance and driving business expansions, executing comprehensive strategic plans that align with organizational objectives and market trends.  Saroj Singh’s deep rooted knowledge in drug discovery and development process and commitment to excellence, positions him as a trusted leader.

Sachin Madan has over 20 years of experience in synthetic as well as medicinal chemistry. He has done postdocs in US, Taiwan and worked previously at TCG Life Sciences, Sai Life Sciences, Lupin Ltd and Laxai Life Sciences. He has led several drug discovery projects in various therapeutic areas like oncology, neuropathic pain, endocrinology, thrombocytopenia, anti-viral agents etc. While heading medicinal chemistry department at Laxai Life Sciences, Sachin has designed and developed the lead molecule, APL-581, in the area of myelofibrosis. This molecule, a dual BET/Kinase inhibitor for hematologic cancers, went into a license agreement for $125M. He has several publications and 5 patents in his name. Sachin heads medicinal chemistry department at TheraIndx Lifesciences.